Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1117)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Vergleichen Sie CTOR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	1.134	95.82M	0	0	0	0.00
ZTS Zoetis Inc	126.16	55.90B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	16.32	51.72B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.91	44.71B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	32.08	37.30B	16.88B	666.71M	251.19M	0.6132
RGC Regencell Bioscience Holdings Ltd	48.91	20.48B	0	-5.87M	-767.30K	-0.45

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-23	Hochstufung	Maxim Group	Hold → Buy
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Vergleichen Sie CTOR mit anderen Aktien

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Why Citius Oncology Inc. stock attracts global investors2025 Price Targets & Low Drawdown Momentum Ideas - ulpravda.ru

Can Citius Oncology Inc. stock beat market expectations this quarterEarnings Performance Report & Technical Pattern Based Signals - ulpravda.ru

How buybacks impact Citius Oncology Inc. stock valueEarnings Growth Report & Expert Curated Trade Setups - ulpravda.ru

Aug Sectors: Why Citius Oncology Inc. stock attracts global investorsTrade Analysis Report & Weekly Watchlist of Top Performers - ulpravda.ru

Does Citius Oncology Inc. stock trade at a discount to peersMarket Risk Report & Momentum Based Trading Signals - ulpravda.ru

Citius Oncology, Inc.Common Stock (NQ: CTOR - FinancialContent

Citius Oncology raises $18M through direct offering - MSN

News | postregister.comCitius Oncology, Inc.Common Stock (Nasdaq:CTOR) Price Chart - FinancialContent

Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - marketscreener.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - Prime Publishers, Inc.

Citius Oncology announces pricing of $9 million public offering - MSN

What drives Citius Oncology Inc stock priceVolatility Trading Techniques & You’ve Never Seen Stock Picks Like These - earlytimes.in

Is Citius Oncology Inc a good long term investmentBear Market Strategies & Low Entry Risk Stocks - earlytimes.in

Earnings Miss: Will Citius Oncology Inc stock sustain high P E ratiosJuly 2025 Institutional & Verified Technical Signals - moha.gov.vn

Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Increase in Short Interest - Defense World

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - 富途牛牛

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga France

Citius Oncology’s Lymphir FDA win clouded by high upfront costs, regulatory risks, and uncertain market adoption - MSN

Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption - TipRanks

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga

Citius Oncology, Inc. Full Year Loss Increases - Nasdaq

Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent

Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results - MarketBeat

Citius Oncology Fiscal 2025 Loss Widens - marketscreener.com

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News

Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com

Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com

Citius Oncology Earnings Notes - Trefis

Citius Oncology, Inc.(NasdaqCM: CTOR) added to Russell 3000E Growth Index - MarketScreener

Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - MSN

Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria

Citius Oncology Raises $18M Through Direct Offering - TipRanks

Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus

Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com

Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat

Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada

Citius Oncology, Inc. announced that it has received $16.6 million in funding - marketscreener.com

Citius Oncology (NASDAQ: CTOR) raises $1.4M, adds large warrant package - Stock Titan

Citius Oncology added to the Russell Microcap Index - MSN

Citius Oncology shares sink after announcing $18M fundraising deal - MSN

Citius Oncology raises $18 million to support cancer therapy launch - Investing.com

Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com Nigeria

Citius Oncology stock tumbles after $18M capital raise - Investing.com India

Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com

Press Release: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - 富途牛牛

Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR